Although CD73 has been validated as an effective prognostic biomarker in numerous cancers, its specific role in endometrial cancer remains to be elucidated, particularly its molecular mechanisms in tumor immune regulation and metastasis, and its potential for personalized therapeutic approaches. This evidence concerns the gene NT5E and neoplasm.